Abstract
Since most diseases are not caused by the deficiency of a single molecule but develop due to changes in the interactions of a variety of cell compo-
nents, such cell-based therapies may prove to be more successful than classical therapies by providing a more dynamic therapeutic approach capable of responding to the individual pathophysiological conditions [1] . In this regard, one of the most promising cell-based therapeutic applications are the innovative approaches for tissue regeneration or replacement, using cells to rebuild or replace damaged organs and tissues [2] . [4] [5] [6] . Due to safety concerns the utilization of immortalized cells is still not a real alternative [7] . Currently cell-based approaches focus on adult tissue-specific stem cell expansion but in the future this might possibly change depending on the ongoing discussion addressing the use of human embryonic stem (ES) cells. [1] .
The basic problem for every cell-based therapy is cell sourcing since cells have to be expanded into large enough quantities while maintaining uniformity in function. Cell expansion as well as uniformity requirement are dependent on the proliferation capacity of either stem/progenitor or already differentiated cells. The use of human embryonic versus adult stem cells is still under scientific/ethical debate [3]. The extent of adult stem cell plasticity which could provide access to novel sources of (trans-) differentiated cells has been questioned by recent reports demonstrating stem cell fusion with tissuespecific differentiated cells rather than true stem cell transdifferentiation with normal diploid chromosomal numbers

Besides autologous also non-autologous human cells may be taken into consideration in the formulation of a cell-based therapy. However, non-autologous cells must be protected from the natural immunologic rejection process of the host thereby limiting this approach. Microencapsulation of the transplanted material [8], development of better immunosuppressant therapies or tolerance induction are fields of research awaiting progress before such allotransplantats will enter clinical routine. Also the use of autologous cells has its own problems since it requires obtaining the patient's own cells, expand them in vitro to large quantities over a more or less long period of time and then transplant them in a site-specific manner. Therefore, each treatment is an individualized and non-scalable process with substantial logistical and regulatory problems including maintenance of the uniform quality of cells, avoidance of introduced pathogens during cell processing, and potential retrievability after implantation
A final obstacle that has to be tackled for cellbased therapies is the maintenance of cell viability during long-term implantation. Long-term function of the transplanted cells is only possible upon successful integration after transplantation and adequate nutrient and oxygen delivery to the cellular implant. [9] .
Human islet transplantation
Although cell-based therapy has substantial technological, regulatory and ethical barriers, the potential to develop new treatment modalities for a large number of clinical disorders is expanding rapidly. Type 1 diabetic patients will probably be one of the major beneficiaries from the advancement of regenerative medicine through cellular therapies. Type 1 diabetes mellitus results from the immune destruction of insulin producing ␤-cells, located in the pancreatic islets of Langerhans
Diabetes prevalence (type 1 and 2) has increased from a world estimate of 135 million in 1995 to 180 million currently, and is predicted to rise to 300 million by the year 2025 [10] .
Although insulin therapy has saved the lives of diabetic patients, diabetics still are in danger to develop chronic diabetes-related complications such as renal failure, myocardial infarction, blindness or vascular problems, that appear years after the onset of diabetes and contribute to shortened lifespan [11, 12] . Such complications not only diminish the quality of life of patients but also represent a burden for health care systems [13, 14] . Although several clinical trials have shown that a strict glycemic control can slow and even prevent the progression of diabetic complications, such an intensive insulin therapy on the other hand increases the incidence of hypoglycaemic episodes and is suitable only for selected patients [15, 16] .
As an alternative, pancreas and islet transplantation have been shown to be efficient in replacing the function of the impaired islets and, thus induce continuous normoglycaemia. The freedom from daily insulin injections and blood glucose monitoring is reported to improve the successfully transplanted recipient's sense of well being, independence, and promote a perception of normality [17] . [19] , which were followed by the first successful islet infusion using the intra-hepatic approach [20] , which is nowadays the classical transplantation site for human islets. Since 1993, pancreatic islet therapy has become subject to regulation by the U.S. Food and Drug Administration as biologic product [21] . Based on the exceptionally successful study of Shapiro et al. at the University of Alberta in Edmonton, Canada, in which seven patients out of seven were insulin-free at the end of one year after islet transplantation [22] , an exponential increase in clinical islet transplantation followed [23] .
However, follow-up investigations have revealed a progressive attrition of the grafted islets with less than 10% of patients remaining insulin-free after 5 years despite most patients having more than one transplant [24] .
The most ambitious goal of allogenic islet transplantation is to establish long-term normoglycaemia and phasic insulin secretion and thereby achieve prolonged insulin independence in the diabetic patient; a goal already achieved in islet autotransplantation for treatment of chronic painful pancreatitis in non-diabetic patients (Fig. 1) [30] . Taking also into account that almost all islet recipients currently require islets from 2-4 donors, then only less than 1000 recipients per year (out of the 17 million in need) could benefit from an islet transplantation [17] .
In addition, the quality of isolated islets is still poorly defined and the functional potential of transplanted islets are difficult to predict. Current standard assays for islet product release criteria are still unable to predict the outcome after clinical islet transplantation [31] . Therefore Fig. 2A) , localization of oligosaccharides on the cell surfaces ( Fig. 2A and B) , calcium (Fig. 2B) , cell death and apoptosis (Fig. 2C) . Confocal microscopy was performed with a microlens-enhanced Nipkow disk-based confocal system mounted on an inverse [23] . The biological proof of principle showing a long-lasting and stable insulin production of islets transplanted into the liver has already been shown in autotransplantations [29] . Although the current immunosuppressive therapies have improved the outcome of islet allotransplantations, most patients once they reach 5 years post-transplantation do not sustain insulin independence [24] . [16] . Despite their in vivo self-replication potential [33] , differentiated ␤-cells cannot be expanded efficiently in vitro [34] . Therefore alternatives are being explored to generate cell-replacement therapies for diabetics. [35] [36] [37] [38] . This also holds true for xenotransplantations, especially those using porcine islets as a source. Concerns about transmission of [21] .
-cells also embryonal stem cells bear the danger of oncologic transformations due to the many necessary in vitro population doublings. Another possibility is the use of xeno-islets, such as procine islets, for transplantation. Although having the advantage of being a sustainable islet source, many obstacles such as the antigenicity (due to the ␣-galactosyl antigen which is present in most non-human primates) and infection with zoonoses (such as the pig endogenous retroviruses) still remain
Fig. 2A Confocal real time microscopy of an entrapped human islet stained with tetramethylrhodamine methyl ester perchlorate (TMRM; red) and Alexa Fluor labeled wheat germ agglutinin (WGA; green). Vital mitochondria with an intact potential appear in red due to the TMRM staining. While islet (dotted line) mitochondria show a significantly higher vitality (see arrow), compared with the surrounding exocrine cells, the glycoconjugates, stained via WGA, at the membrane surfaces are present in a significantly higher amount in the exocrine cells (see asterisks) compared with the islet cells.
microscope. Especially in light of the many other fluorescent dyes which can be used as sub-cellular markers, a combination of these with a confocal system allowing live cell imaging will be of great value for a better and faster cell quality assessment after isolation, culture and transport of human islet cells. Besides these advantages, live confocal imaging may yield new insights into the biology of human islets and thereby help us answering the still open question in islet transplantation: How can the current disparity between supply and demand be tackled? Only when new sources of pancreatic islets or ␤-cells are found, cell replacement as a treatment for diabetes will become widely available
In search of an "endless pool" of ␤-cells: embryonic stem cells, adult mesenchymal stem cells, progenitor cells, cell lines and xenotransplantations
The shortage of primary human islets has led to several efforts to identify and create high numbers of ␤-cells that can be used for regulated insulin therapy. Approaches to generate ␤-cells from embryonic or adult stem cells or by transdifferentiation from other cell types such as liver cells or exocrine/ductal pancreatic cells are still far away from reaching the stage of clinical application
Fig. 2C Confocal real time microscopy of a human islet isolation stained with propidium iodide (PI; red; see arrows) and the FITC labeled apoptosis marker annexin V (green; see asterisks). Confocal microscopy was performed with a microlens-enhanced
Another possible strategy to generate human pancreatic ␤-cells in sufficient quantity is to transform human primary ␤-cells with immortalizing genes and excise these potentially tumorigenic genes after propagation before the final recovery of primary ␤-cell function.
Recently such an approach yielded a reversibly immortalized human ␤-cell line [40] . (Fig. 4) .
The immortalized cell line was generated by transformation of human islet cells with retroviral vectors expressing SV40 large T-antigen (SV40T) and human telomerase reverse transcriptase (TERT
The ␤-cell mass plays an important role in determining the amount of insulin that is secreted in order to maintain the body's glucose levels within a narrow range. Therefore, the regulation of ␤-cell mass is crucial, especially taking into consideration its dynamic nature depending on the demand of insulin needed. Besides functional adaptations, such as changes in threshold for glucose induced insulin secretion during pregnancy [48] , the ␤-cell mass itself is the major factor in the amount of insulin that can be secreted [49] . As shown in a morphometric study using autopsied pancreata from non-insulin-dependent diabetes mellitus patients (NIDDM) and non-diabetic patients, in the diabetic as well as the non-diabetic patient, the ␤-cell mass was approximately 40% increased in the obese as compared with the lean patients, indicating a compensatory growth of the ␤-cell mass [50] [52] . [55] [56] . Soria, 2001 [43] . [58] . Notably, Raf-1 kinase inhibitory protein (RKIP), which has been shown to inhibit the ERK-signalling pathway [59] was shown to be present in most pancreatic ␤-cells as well as in a subset of pancreatic polypeptide-expressing cells [60] . [61] .
After the mitogenic stimulus Dcyclins associate with partner cyclin-dependent kinases CDK4 and CDK6 thereby driving cells into Sphase [53]. From the three D-cyclins, primarily cyclin D2 is required for ␤-cell replication and proper expansion of ␤-cell mass during the murine postnatal development of the pancreas. While replication of exocrine and ductal cells is unperturbed in cyclin D2 deficient mice, the absence of endocrine cell replication in these mice results in a 3-fold decrease in ␤-cell mass [42]. Whereas in the majority of other cell types up-regulation of the remaining D-cyclins can compensate for the loss of any particular D-cyclin [54], this does not seem to be the case in pancreatic ␤-cells. The inability of ␤-cells to up-regulate other Dcyclins in early postnatal development indicates that the mitotic signaling mediating the high rates of ␤-cell replication specifically depends on cyclin D2 [42]. Such a rigid connection of the signalling pathway to the cell cycle machinery in ␤-cells may offer an opportunity for selective intervention during the course of islet transplantation in order to either propagate ␤-cells in vitro or give them the proper mitotic stimulus before transplanting them into the liver. Before such new strategies can be tackled, a better understanding of the cell cycle progression and regulation of ␤-cells is needed. Especially, as it is known that forcing endocrine cells to re-enter the cell cycle may trigger programmed cell death
Interestingly, the analogue of glucagon-like peptide 1, exendin-4, which is also known to augment pancreatic islet mass and ␤-cell proliferation, was shown to increase cyclin D1 expression when administered to the pancreatic ␤-cell line INS-1 [57]. In addition, the same study described an exendin-4 induced phosphorylation of Raf-1 and extracellularsignal-regulated kinase (ERK). Recently ERK1/2
Fig. 3 Schematic model proposing four different molecular control levels of pancreatic ␤-cell proliferation and differentiation. For a more detailed description of the extrinsic factors influencing ␤-cell proliferation and differentiation see
Pancreatic ␤-cell growth and differentiation requires precise control of the molecular mechanisms leading to either entry or exit of a replicative or differentiated state. A, B, C and D symbolize different control levels. Developmental state, age, metabolic factors, injuries or diseases such as diabetes affect both proliferation as well as differentiation of ␤-cells. Local signals coming either from surrounding cells or the extracellular matrix balance the proliferation and differentiation status of ␤-cells and thereby also their function. As impressively documented by islet autotransplantation, ␤-cells can handle with "big changes" i.e. even the transplantation into another organ such as the liver. The questions are how big the dependence of the ␤-cells is concerning an intact cytoarchitecture of the transplanted islet and how much help coming from the neighbouring cells, is needed (see also Figure 4)? Answering these questions is fundamental for further cell therapeutic approaches aiming at an expansion of the available pool of human ␤-cells.
were reported to control phosphorylation of the cAMP-responsive element-binding protein (CREB) thereby playing a key role in glucose-mediated pancreatic ␤-cell survival
Besides showing a down-regulation of RKIP in human insulinomas, the authors used antisense technology in the transformed hamster ␤-cell line HIT-T15 to document an inhibitory role of RKIP in ␤-cell proliferation. While it is very probable that ␤-cell growth is influenced by RKIP via the ERK-signalling pathway, additional interactions of RKIP with other signalling pathways cannot be ruled out. Signal transducer and activator of transcription 5 (STAT5) activation was shown to play a key role in growth hormone (GH) and prolactin-mediated transcriptional induction of cyclin D2 in rat pancreatic ␤-cells. The authors concluded that STAT5 activation is sufficient to drive proliferation of the ␤-cells and that cyclin D2 may be a critical target gene for STAT5 in this process
After their interaction with cyclins, cyclin-dependent kinases Cdk4 and Cdk6 translate the mitotic stimulus by phosphorylation and subsequent inactivation of the retinoblastoma gene products pRb and
pRb-related proteins [53] . Upon phosphorylation, pRb releases tethered transcription factor E2F and irreversibly commits the cell to progress through the cell cycle [62] 
Revascularization of transplanted islets
There is still a need for more intensive research designed to characterize and improve the environment into which islets are being transplanted. A better knowledge of the local cellular and molecular changes taking place after islet transplantation into the liver will yield the necessary basis for a more successful islet implantation. The influence of the surrounding tissue on islet physiology can be demonstrated for the release of glucagon: while islets transplanted into the peritoneal cavity release glucagon normally during hypgoglycaemia [71] , this is not the case when the islets are transplanted intrahepatically [72] . It will be interesting to see, whether such differences in islet function might be attributed e.g. to differences in the vascular basement membrane composition dependent on the implantation site.
Up to now, most of the attention and discussions in the field of islet transplantation focused on ␤-cells and their precursors/progenitors or stem cells [21, 35, 36, 73, 74] [80, 81] . In pancreas development signals from blood vessel endothelium induce islet formation [81] . Thereafter islets signal in a paracrine fashion via VEGF-A to the endothelium which then forms the dense vascular network which is known to be required for proper endocrine function and islet size [82] . The future will show to what extent other "helper" cells are needed to guarantee a reproducible and long-lasting propagation and function of human ␤-cells (Fig. 5A) (Fig. 5B); (ii ) the basement membrane components produced by the endothelial cells promote ␤-cell proliferation and insulin gene expression [83] . This might explain why islets maintain a capillary network that is five times denser than that of the exocrine pancreatic tissue and therefore exceeds the general tissue requirement for vascular supply [84] .
Therefore, when talking about islet transplantation also endothelial cells should be taken into consideration. Especially as it is known that the enzymatic digestion procedure used to isolate islets partially removes intra-islet endothelial cells thereby contributing to transplant failure [85, 86] 
